LHRH Receptor Targeting Against Cancer
Tumor-Targeting Peptides
80-90% of ovarian/prostate tumors
LHRH receptors are overexpressed in up to 90% of prostate and 80% of ovarian cancers but absent from most normal organs, creating an ideal target for peptide-guided drug delivery.
Nayak et al., Int J Mol Sci, 2025
Nayak et al., Int J Mol Sci, 2025
View as imageThe same peptide system that controls puberty and fertility has a second life in oncology. Luteinizing hormone-releasing hormone (LHRH, also called GnRH) receptors are expressed at high density on the surface of prostate, breast, ovarian, and endometrial cancer cells, while most normal visceral organs do not express them at detectable levels.[1] This differential expression creates a targeting opportunity: attach a cytotoxic drug to an LHRH analog, and the conjugate homes specifically to tumor cells expressing the receptor, delivering chemotherapy directly while sparing healthy tissue. The approach has produced peptide-drug conjugates that reached Phase III clinical trials and a growing class of theranostic agents for imaging and treatment. For context on how GnRH agonists suppress testosterone to treat prostate cancer through hormonal deprivation (a different mechanism), see the dedicated article. This article focuses on LHRH as a homing address for targeted drug delivery, which is fundamentally different from hormonal suppression. The broader field of tumor-targeting peptides includes RGD peptides, bombesin, and somatostatin analogs, each exploiting different receptor overexpression patterns.
Key Takeaways
- LHRH receptors are overexpressed in approximately 86% of prostate, 80% of endometrial, 80% of ovarian, and 50% of breast cancers, but absent from most normal visceral organs (Giorgio et al., 2025)
- AEZS-108 (zoptarelin doxorubicin), a [d-Lys6]-GnRH-doxorubicin conjugate, reached Phase III clinical trials for endometrial cancer before failing its primary endpoint
- Peptide-drug conjugates using LHRH targeting deliver cytotoxic payloads directly to tumor cells, reducing systemic toxicity compared to free chemotherapy (Ma et al., 2017)
- EP-100, a LHRH-lytic peptide conjugate, disrupts tumor cell membranes through a mechanism entirely different from conventional chemotherapy
- Radiolabeled LHRH analogs serve as theranostic agents, combining diagnostic imaging with targeted radiation therapy in a single molecule (Giorgio et al., 2025)
Why Tumors Express LHRH Receptors
LHRH receptors (LHRH-R, also called GnRH-R) evolved to be expressed on pituitary gonadotroph cells, where they receive the hypothalamic GnRH signal that drives LH and FSH release. In normal physiology, expression outside the pituitary is minimal.
But many cancers ectopically express LHRH-R at high density. Giorgio et al. (2025) conducted a systematic review of radiolabeled LHRH analogs and confirmed receptor overexpression across multiple tumor types.[2] Nayak et al. (2025) focused specifically on ovarian cancer, where LHRH-R expression reaches approximately 80% of tumors, and reviewed how this expression pattern enables targeted treatment strategies.[1]
The reasons tumors express these receptors are not fully understood. Possible explanations include:
- Autocrine/paracrine signaling: some tumors produce GnRH locally and use it to regulate their own growth (both stimulatory and inhibitory effects have been documented)
- Dedifferentiation: cancer cells may reactivate developmental gene programs that include LHRH-R expression
- Selective pressure: LHRH-R signaling may provide growth or survival advantages in certain tumor microenvironments
Whatever the cause, the clinical relevance is pragmatic: LHRH-R is present on tumor cells and absent from most normal tissues, making it a valid homing target for drug delivery.
Peptide-Drug Conjugates: The LHRH Delivery System
A peptide-drug conjugate (PDC) consists of three components: a targeting peptide (the LHRH analog), a cytotoxic payload (a chemotherapy drug or lytic peptide), and a linker connecting them. The conjugate circulates in the blood, binds to LHRH-R on tumor cells, is internalized by receptor-mediated endocytosis, and releases its payload inside the cancer cell.[3]
Ma et al. (2017) reviewed the PDC concept, comparing it to the more established antibody-drug conjugates (ADCs) like trastuzumab emtansine (Kadcyla). PDCs offer several advantages over ADCs: smaller molecular size (better tumor penetration), lower immunogenicity (less likely to trigger immune reactions), simpler manufacturing (chemical synthesis rather than biological production), and lower cost.[3]
The tradeoffs are shorter plasma half-life (peptides are cleared faster than antibodies) and potentially lower binding affinity (though LHRH analogs bind LHRH-R with nanomolar affinity, comparable to antibody-antigen interactions).
AEZS-108 (Zoptarelin Doxorubicin)
The most clinically advanced LHRH-targeted PDC is AEZS-108, composed of doxorubicin (a potent but toxic chemotherapy agent) linked to [d-Lys6]-GnRH-I, a synthetic LHRH agonist. The conjugate binds LHRH-R, is internalized, and releases doxorubicin inside the tumor cell after lysosomal cleavage of the ester linker.
In preclinical models, AEZS-108 showed equivalent or superior antitumor activity compared to free doxorubicin, with reduced cardiotoxicity (doxorubicin's dose-limiting side effect). The conjugate progressed through Phase I and II trials showing activity in LHRH-R-positive endometrial, ovarian, and prostate cancers.
AEZS-108 reached Phase III in advanced endometrial cancer but failed to meet its primary overall survival endpoint. The failure may reflect patient selection (not all enrolled patients were confirmed LHRH-R positive), linker instability (premature doxorubicin release in circulation), or insufficient drug delivery to achieve therapeutic concentrations. The compound's clinical development has not continued, but it validated the LHRH-targeting concept and informed next-generation designs.
EP-100: The Membrane-Disrupting Approach
EP-100 uses a different payload strategy. Instead of a conventional chemotherapy drug, it links an LHRH agonist to a cationic amphipathic peptide (CLIP-71) that physically disrupts cell membranes. Cancer cell membranes carry a higher negative surface charge than normal cells (due to increased phosphatidylserine exposure and altered glycosylation), making them more susceptible to cationic membrane-disrupting agents.
EP-100 binds LHRH-R, concentrates at the tumor cell surface, and induces rapid membrane lysis. This mechanism is fundamentally different from conventional chemotherapy: it does not require cell internalization, is not affected by multidrug resistance pumps, and kills cancer cells within minutes rather than hours or days.
Theranostics: Imaging and Treating with the Same Molecule
Giorgio et al. (2025) systematically reviewed radiolabeled LHRH analogs that serve as theranostic agents. By conjugating a radioactive isotope to an LHRH analog, the same molecule can be used for diagnostic imaging (to locate LHRH-R-expressing tumors) and targeted radiotherapy (to deliver lethal radiation doses to those tumors).[2]
This theranostic approach mirrors the somatostatin analog paradigm already established for neuroendocrine tumors, where 68Ga-DOTATATE PET imaging identifies somatostatin receptor-positive tumors and 177Lu-DOTATATE delivers therapeutic radiation to the same targets. LHRH-based theranostics aim to extend this model to prostate, breast, ovarian, and endometrial cancers.
The field is early-stage. Most LHRH radioligands have been tested in cell culture binding assays and small animal models. Challenges include achieving sufficient tumor uptake relative to kidney accumulation (a common problem with peptide radioligands), optimizing the LHRH analog for receptor binding while maintaining radiochemical stability, and selecting appropriate isotopes for each application (68Ga or 18F for PET imaging; 177Lu, 90Y, or 225Ac for therapy).
Advantages of LHRH Targeting Over Hormonal Suppression
LHRH agonists (leuprolide, goserelin) and antagonists (degarelix) are already FDA-approved for prostate cancer and breast cancer, but they work through hormonal suppression: shutting down testosterone or estrogen production. The PDC approach is fundamentally different.
| Feature | Hormonal LHRH Agonists | LHRH-Targeted PDCs |
|---|---|---|
| Mechanism | Suppress sex hormones | Deliver cytotoxic payload to tumor |
| Target | Pituitary LHRH-R | Tumor LHRH-R |
| Effect on tumor | Indirect (hormone deprivation) | Direct (drug or radiation delivery) |
| Useful in hormone-independent cancer | No | Yes (if LHRH-R expressed) |
| Side effects | Hot flashes, bone loss, metabolic effects | Potentially reduced systemic toxicity |
The distinction matters because many cancers that initially respond to hormonal suppression eventually become castration-resistant (hormone-independent), at which point hormonal LHRH agonists lose their efficacy. LHRH-targeted PDCs can still work in castration-resistant disease, as long as the tumor continues to express LHRH-R, which many castration-resistant prostate cancers do.
Next-Generation Designs
Rizvi et al. (2024) reviewed the chemistry of peptide-drug conjugate design, identifying key optimization parameters.[4] Armstrong et al. (2025) provided an updated perspective on the entire PDC field.[5] Next-generation LHRH-targeted PDCs are incorporating:
- Cleavable linkers: protease-sensitive or acid-labile linkers that release the payload only inside tumor cells (reducing premature drug release in circulation)
- More potent payloads: auristatins, maytansinoids, and camptothecin derivatives that are 100-1000x more potent than doxorubicin, allowing lower drug loading
- Dual-targeting: conjugates that combine LHRH targeting with a second homing peptide (e.g., RGD for integrin targeting) to increase tumor specificity
- Multivalent constructs: dendrimers or nanoparticles decorated with multiple LHRH targeting peptides to increase avidity
Limitations
LHRH receptor targeting has clear constraints:
Not all tumors express LHRH-R. While 80-90% of prostate and ovarian cancers are LHRH-R positive, 10-20% are not. Patient selection through companion diagnostic imaging (ideally using a radiolabeled LHRH analog) would be necessary for effective clinical use.
The Phase III failure of AEZS-108 demonstrates the gap between preclinical promise and clinical efficacy. Tumor penetration, linker stability, and drug release kinetics in humans may differ substantially from mouse models.
Receptor downregulation after repeated exposure is a theoretical concern. If LHRH-R is internalized and not recycled efficiently, chronic PDC administration could reduce the target density on tumor cells.
The kidney is the primary organ for peptide clearance, and renal accumulation of peptide radioligands can cause nephrotoxicity. This is a recognized problem in somatostatin-based theranostics and applies equally to LHRH radioligands.
No LHRH-targeted PDC is currently approved for clinical use. The field has validated the concept but has not yet produced a commercially available drug. Multiple candidates are in preclinical and early clinical development.
The Bottom Line
LHRH receptors are overexpressed in 50-90% of prostate, breast, ovarian, and endometrial cancers while absent from most normal organs, making them an attractive target for peptide-guided drug delivery. Peptide-drug conjugates linking LHRH analogs to cytotoxic payloads (AEZS-108, EP-100) have reached clinical trials, and radiolabeled LHRH analogs show theranostic potential for simultaneous imaging and targeted radiation therapy. The Phase III failure of AEZS-108 in endometrial cancer tempered enthusiasm but did not invalidate the targeting concept. Next-generation conjugates with improved linkers, more potent payloads, and companion diagnostics are in development.